Weekly Investment Analysts’ Ratings Updates for Guardant Health (GH)

Several analysts have recently updated their ratings and price targets for Guardant Health (NASDAQ: GH):

• 2/26/2025 – Guardant Health had its price target raised by analysts at Piper Sandler from $34.00 to $50.00. They now have an “overweight” rating on the stock.
• 2/24/2025 – Guardant Health had its price target raised by analysts at Scotiabank from $47.00 to $52.00. They now have a “sector outperform” rating on the stock.
• 2/24/2025 – Guardant Health had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $56.00 price target on the stock.
• 2/24/2025 – Guardant Health had its price target raised by analysts at Canaccord Genuity Group Inc. from $42.00 to $60.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Guardant Health had its price target raised by analysts at JPMorgan Chase & Co. from $50.00 to $55.00. They now have an “overweight” rating on the stock.
• 2/21/2025 – Guardant Health had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $59.00 price target on the stock, up previously from $39.00.
• 2/21/2025 – Guardant Health had its price target raised by analysts at The Goldman Sachs Group, Inc. from $49.00 to $56.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Guardant Health had its price target raised by analysts at Stifel Nicolaus from $45.00 to $53.00. They now have a “buy” rating on the stock.
• 1/28/2025 – Guardant Health had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $49.00. They now have a “buy” rating on the stock.
• 1/23/2025 – Guardant Health is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $60.00 price target on the stock.
• 1/22/2025 – Guardant Health had its “buy” rating reaffirmed by analysts at Guggenheim.

Guardant Health Stock Performance

NASDAQ:GH opened at $42.11 on Friday. The company has a 50-day moving average of $40.87 and a 200-day moving average of $31.89. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The company has a market capitalization of $5.20 billion, a price-to-earnings ratio of -11.83 and a beta of 1.32.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Activity

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 2,768 shares of company stock worth $98,798. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

A number of large investors have recently modified their holdings of the stock. JNBA Financial Advisors bought a new position in Guardant Health in the 3rd quarter worth approximately $26,000. R Squared Ltd acquired a new stake in shares of Guardant Health in the 4th quarter valued at $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Guardant Health during the third quarter worth $34,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health during the fourth quarter valued at $43,000. Finally, Kimelman & Baird LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at $58,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.